Navigation Links
DelSite Working Toward Solving Delivery of Influenza Vaccine in Pandemic Situations

e U.S. for production of vaccine antigens. This egg-based manufacturing process requires a minimum of six months. The newest technology available uses a mammalian cell line to produce antigens. This cell-based technology is more efficient, faster, and eliminates allergic problems caused by egg proteins.

DelSite's GelVac(TM) powder vaccine technology works with egg- or cell-based antigen. In addition, the use of a whole virus (whole virion) provides more potent vaccines than vaccines produced using split or partial parts of the virus; the GelVac(TM) technology may be used to deliver vaccines made from any of these methods.

DelSite's GelVac(TM) platform is based on the GelSite(R) polymer, a negatively-charged linear polymer with a molecular weight greater than 450,000 which is derived from a natural source and is classified as a GRAS (generally regarded as safe) by the FDA.

GelSite(R) is produced in kilogram quantities under FDA good manufacturing practices for human drugs (cGMP) in an ISO-certified facility. Each kilogram of the GelSite(R) polymer can be used to manufacture approximately 5 to 8 million vaccine doses. Plant material used in the production of GelSite(R) polymer is recognized as certified organic by the U.S. Department of Agriculture, European Union and government of Costa Rica.

After the Influenza Conference concluded, Dr. Yawei Ni, chief scientific officer of DelSite, stated, "Our GelVac(TM) powder vaccine delivery platform was the only powder system at the conference, and I believe it can be used to solve or alleviate basic technology problems that would be created by a worldwide pandemic. We have completed the Phase I safety study for the powder system and will file an IND with the FDA for a Phase I clinical study using a H5N1 antigen later this year."


'"/>




Page: 1 2 3

Related medicine news :

1. Working in shifts may cause damage to your health
2. Junior Doctors Working Long Hours May Perform Poorly
3. New UK Policy Threatens The Flexible Working Scheme
4. Medicare Drug Plan Is Not Working in The US
5. Warning! Working For Long Hours On Your Computer Can Be Lethal
6. Stressed Pregnant Working Mothers Put Their Unborn Child’s Life in Dange
7. Working of Drug Department on Hold Without Drug Analyst
8. Doctor Faces Disbarment For Working In Multiple Hospitals
9. Computational Model Reveals Working of AZT in Body
10. Scientists Working On Drug Trial Guidelines
11. Scientists Uncover Complex Workings of Sperm
Post Your Comments:
(Date:12/4/2008)...er 4, 2008) - An Ontario study of 491 women with ...ion, 19%, were referred for genetic testing of BRC... family members are not informed of their cancer r...or at the University of Toronto,s Lawrence S. Bloo... at Women,s College Research Institute, led the nu...
(Date:12/4/2008)... Reawakening a dormant gene could ease sick... (Vocus) December 4, 2008 -- Researchers a...al.org ) and Dana-Farber Cancer Institute have ide...form of hemoglobin normally made only before birth...form sickle-cell disease and beta-thalassemia -- l...
(Date:12/4/2008)...Dec. 4 NAMC members can gain acces...desktop. Webinars feature nationally-recognized sp...ter. The next webinar will be on December 10, 200...e Audience , Do you know where your online infl..., do you know how to engage them? , This webin...
(Date:12/4/2008)... Dr. Stephen Joffe, Craig Joffe, a...Schedule 13D with the U.S.,Securities and Exchang...isclosing ownership of 11.4% of LCA-Vision, Inc. (...ed-site laser vision correction centers in 33 stat...r and former Chairman and CEO of,LCAV. Craig Jof...
Breaking Medicine News(10 mins):Health News:Few Ontario women with invasive ovarian cancer referred for genetic testing of breast cancer genes 2Health News:Turning back the Clock in Inherited Anemias 2Health News:Turning back the Clock in Inherited Anemias 3Health News:Turning back the Clock in Inherited Anemias 4Health News:New NAMC Member Service! Complimentary Webinars for NAMC Members - On Topics You Need to Know! Sign Up Today for This New and Exciting Educational Program! 2Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 2Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 3Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 4Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 5Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 6
...r Disease Control and Prevention (CDC) shows that ...ve among teenagers.// The CDC defines binge drin..." and the National Institute of Alcohol Abuse and ...attern of drinking that brings a person’s blood al...
...the US the present guidelines should be modified a...rnal of Respiratory and// Critical Care Medicine. ...fied as "high-risk,” when they have originally com...This paper has been published by American Thoracic...
...ring during the winter cold and flu season//, a vo...alth System is offering tips for preventing and tr...e of voice change that can accompany the common co... something that is quite common, and I’m sure most...
...lung function who later develop chronic cough and ... chronic obstructive pulmonary disease (COPD). The...in the first issue for January 2007 of the America... Care Medicine, published by the American Thoracic...
Other Medicine News:Health News:TB can Be Eradicated in the U.S With Modified Guidelines: Study 2Health News:Tips to Prevent and Treat Winter Laryngitis 2Health News:Cough and Phlegm Cause Fourfold Increase in COPD Incidence 2
(Date:12/3/2008)... NEWARK, Del., Dec. 3 Isogen, a c...n for sterile filling, announced it has retained a...erations to meet the global,biopharma demand for ...announced a successful first round series of capit...g line facility in Q1 2009 to,deliver on the prev...
(Date:12/2/2008)... CHICAGO, Dec. 3 Breas...he detection of cancers not found on mammograms or... today at the annual meeting of,the Radiological ...n identify the most difficult to detect breast can... Rachel F. Brem, M.D., professor of,radiology and...
(Date:12/2/2008)... BETHESDA, Md., Dec. 2 ...cal company developing novel, proprietary antibodi...utoimmune diseases, today announced that it has en...uity Financing Facility (CEFF) with Kingsbridge Ca...the terms of the agreement, Kingsbridge has commit...
(Date:12/1/2008)... SINGAPORE, Dec. 1 S*BIO Pte Ltd ...ical trial of SB1518, a potent and orally-active J...alia for patients with chronic idiopathic myelofib... evaluate the safety and tolerability of SB1518 in... 50 patients. The Phase 1 part of the study will ...
Breaking Medicine Technology:Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 2Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 3New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Ron Greenspan DDS Creates Plan to Eliminate the Barriers to Orthodontic Treatment 23999 1Ron Greenspan DDS Creates Plan to Eliminate the Barriers to Orthodontic Treatment 23999 2AMT Starts Collaboration With St Jude Childrens Research Hospital on Gene Therapy for Hemophilia B Company Accesses Exclusive Commercial Rights to F 6542 1AMT Starts Collaboration With St Jude Childrens Research Hospital on Gene Therapy for Hemophilia B Company Accesses Exclusive Commercial Rights to F 6542 2AMT Starts Collaboration With St Jude Childrens Research Hospital on Gene Therapy for Hemophilia B Company Accesses Exclusive Commercial Rights to F 6542 3AMT Starts Collaboration With St Jude Childrens Research Hospital on Gene Therapy for Hemophilia B Company Accesses Exclusive Commercial Rights to F 6542 4Aggressive preschoolers found to have fewer friends than others 23995 1Aggressive preschoolers found to have fewer friends than others 23995 2Culture and depression 23992 1Culture and depression 23992 2
...wire/ -- Phase 3 results,from the RE-NOVATE(TM) tr...ce daily, administered for an average of 33 days, ...for an average of 33,days, in preventing venous th...total hip replacement surgery. In this trial, the,...etexilate was,similar to enoxaparin. The incidence...
...oper Antisoma plc,(LSE: ASM, US OTC: ATSMY) today ...04 in recurrent, platinum-sensitive ovarian cancer...us chemotherapy,(n=37) with patients receiving che...ollows: , * There was no advantage in median time ...ith the control arm * One-year survival,rates were...
Other Medicine Technology:Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 2Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 3Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 4Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 5Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial 2Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial 3
Each ENDOKNOT™ consists of a 42" long suture inserted into a plastic tube. The plastic tube is narrow at one end and scored on the other. The suture protrudes from the narrow end and swaged to
The ENDOLOOP consists of 18'' long ligature inserted into a plastic tube. The plastic tube is narrow at one end and scored on the other. The suture protrudes from the narrow end and is formed in a li
The ENDOLOOP consists of 18'' long ligature inserted into a plastic tube. The plastic tube is narrow at one end and scored on the other. The suture protrudes from the narrow end and is formed in a li
...201+ is the latest addition to the HemoCue glucose...new system combines the precision and accuracy of ...time and ease of use. The new pocket size analyser... date and time for up to 600 measurements. The sto...
Medicine Products: